Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis

References

• Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum Dis Clin N Am. 1996;22:647–74.
   PubMed Web of Science ®Google Scholar
• LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest. 1974;54:880–9.
   PubMed Web of Science ®Google Scholar
• Asano Y, Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with sys-temic sclerosis. Arthritis Rheum. 2001;44:1363–9.
   PubMed Web of Science ®Google Scholar
• Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, et al. Serum levels of KL-6 as a useful marker for evaluating pul-monary fibrosis in patients with systemic sclerosis. J Rheumatol. 2000;27:930–4.
   PubMed Web of Science ®Google Scholar
• Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA. 1986;83:6692–6.
   PubMed Web of Science ®Google Scholar
• Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun. 2005;73:1271–4.
   Google Scholar
• Sallenave JM, Silva A, Marsden ME, Ryle AP. Secretion of mucus proteinase inhibitor and elafin by Clara cell and type II pneumocyte cell lines. Am J Respir Cell Mol Biol. 1993;8:126–33.
   PubMedGoogle Scholar
• Sallenave JM. The role of secretory leukocyte proteinase inhib-itor and elafin (elastase-specific inhibitor/skin-derived antileu-koprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res. 2000;1:87–92.
   PubMedGoogle Scholar
• Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antag-onistic to bacterial lipopolysaccharide. Cell. 1997;88:417–26.
   PubMed Web of Science ®Google Scholar
• Kammouni W, Figarella C, Baeza N, Marchand S, Merten MD. Pseudomonas aeruginosa lipopolysaccharide induces CF-like alteration of protein secretion by human tracheal gland cells. Biochem Biophys Res Commun. 1997;241:305–11.
   Google Scholar
• Saitoh H, Masuda T, Shimura S, Fushimi T, Shirato K. Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am J Physiol Lung Cell Mol Physiol. 2001;280:L79–87.
   Google Scholar
• van Wetering S, van der Linden AC, van Sterkenburg MA, Rabe KF, Schalkwijk J, Hiemstra PS. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epi-thelial cells: increase of cell-associated SLPI by neutrophil elastase. J Investig Med. 2000;48:359–66.
   PubMed Web of Science ®Google Scholar
• Jin F, Nathan CF, Radzioch D, Ding A. Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun. 1998;66:2447–52.
   PubMed Web of Science ®Google Scholar
• Vos JB, van Sterkenburg MA, Rabe KF, Schalkwijk J, Hiemstra PS, Datson NA. Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early media-tors of host defense. Physiol Genomics. 2005;21:324–36.
   PubMedGoogle Scholar
• Birrer P, McElvaney NG, Rudeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med. 1994;150:207–13.
   Google Scholar
• Masuda K, Suga T, Takeuchi A, Kanesaki M, Imaizumi A, Suzuki Y. Specific cleavage of secretory leukoprotease inhibitor by neutrophil elastase and saliva. Biochem Pharmacol. 1994;48: 651–7.
   PubMedGoogle Scholar
• Pemberton AD, Huntley JF, Miller HR. Differential inhibition of mast cell chymases by secretory leukocyte protease inhibitor. Biochim Biophys Acta. 1998;1379:29–34.
   PubMedGoogle Scholar
• Piccioni PD, Kramps JA, Rudolphus A, Bulgheroni A, Luisetti M. Proteinase/proteinase inhibitor imbalance in sputum sol pha-ses from patients with chronic obstructive pulmonary disease. Suggestions for a key role played by antileukoprotease. Chest. 1992;102:1470–6.
   Google Scholar
• Trefz G, Schliesser J, Heck B, Schulz V, Ebert W. Alpha 1-proteinase inhibitor and mucus proteinase inhibitor in human lung emphysema. Clin Investig. 1992;70: 269–76.
   Google Scholar
• Wiedow 0, Harder J, Bartels J, Streit V, Christophers E. Anti-leukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. Biochem Biophys Res Commun. 1998;248: 904–9.
   Google Scholar
• Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: one glove, many fingers. Clin Sci (Lond). 2006;110:21–35.
   PubMed Web of Science ®Google Scholar
• Weldon S, Taggart CC. Innate host defense functions of secretory leucoprotease inhibitor. Exp Lung Res. 2007;33:485–91.
   PubMed Web of Science ®Google Scholar
• Ameshima S, Ishizaki T, Demura Y, Imamura Y, Miyamori I, Mitsuhashi H. Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma. Cancer. 2000;89:1448–56.
   PubMed Web of Science ®Google Scholar
• Kida K, Mizuuchi T, Takeyama K, Hiratsuka T, Jinno S, Hosoda K, et al. Serum secretory leukoprotease inhibitor levels to diag-nose pneumonia in the elderly. Am Rev Respir Dis. 1992;146:1426–9.
   PubMedGoogle Scholar
• Sallenave JM, Donnelly SC, Grant IS, Robertson C, Gauldie J, Haslett C. Secretory leukocyte proteinase inhibitor is preferen-tially increased in patients with acute respiratory distress syn-drome. Eur Respir J. 1999;13:1029–36.
   PubMedGoogle Scholar
• Tsoumakidou M, Bouloukaki I, Thimaki K, Tzanakis N, Siafakas NM. Innate immunity proteins in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Exp Lung Res. 2010;36:373–80.
   Google Scholar
• LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classifi-cation, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.
   Google Scholar
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581–90.
   PubMed Web of Science ®Google Scholar
• Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. The prevalence and clinical significance of anti-Ul RNA antibodies in patients with systemic sclerosis. J Invest Dermatol. 2003;120:204–10.
   Google Scholar
• Franken C, Meijer CJ, Dijkman JH. Tissue distribution of anti-leukoprotease and lysozyme in humans. J Histochem Cytochem. 1989;37:493–8.
   PubMed Web of Science ®Google Scholar
• Kramps JA, Te Boekhorst AH, Fransen JA, Ginsel LA, Dijkman JH. Antileukoprotease is associated with elastin fibers in the extracellular matrix of the human lung. An immunoelectron microscopic study. Am Rev Respir Dis. 1989;140:471–6.
   PubMedGoogle Scholar
• Van Seuningen I, Audie JP, Gosselin B, Lafitte JJ, Davril M. Expression of human mucous proteinase inhibitor in respiratory tract: a study by in situ hybridization. J Histochem Cytochem. 1995;43:645–8.
   Google Scholar
• Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino35.T, et al. Pulmonary surfactant protein D in sera and bronchoal-veolar lavage fluids. Am J Respir Crit Care Med. 1995;152: 1860–6.36.
   Google Scholar
• Kuroki Y, Takahashi H, Chiba H, Akino T. Surfactant proteins A and D: disease markers. Biochim Biophys Acta. 1998;1408: 334–45. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis. prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136-51. Sugimoto H, Hashimoto N, Ameshima S, Gejyo F, Ishizaki T, Miyabo S. The clinical study on secretory leukoprotease inhibitor (SLPI) in sera of patients with various pulmonary diseases. Rinsho Byori. 1995;43:1267-72. (in Japanese).
   Google Scholar